To ascertain the contribution of IL‐6 signaling on cancer cells to this effect, we knocked down IL‐6 receptor (IL6RA) in the TGFβR2‐mutant cells (Fig 8A) and evaluated the efficacy of TGFβR2 and IL‐6 inhibition in vitro and in vivo. This evidence concerns the gene TGFBR2 and cancer.